Alnylam Pharmaceuticals, Inc. Company Analysis & Research
Alnylam is the pioneer of RNA interference (RNAi) technology and has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the expansion of its flagship drug, Amvuttra, into the multi-billion-dollar Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) market, the company is currently at the center of one of the most significant therapeutic shifts in modern medicine.
With a blockbuster product in Amvuttra, a clear path to sustained profitability, and a platform expanding into massive therapeutic areas like hypertension and Alzheimer's, Alnylam is a rare breed in the biotechnology sector. The company's new five-year strategy, "Alnylam 2030," focuses on scaling operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility.
Company Overview
Founded: 2002. Headquarters: Cambridge, US. Revenue: $3.0B (2025). Ticker: ALNY (NASDAQ).
Industry
Biopharmaceuticals - RNA Interference (RNAi) Therapeutics
Cyborg Score: 8/10 — Strong
Alnylam transitions from speculative biotech to profitable pharma leader with dominant RNAi platform and high-growth blockbuster in competitive ATTR market.
The company achieved $3 billion in revenue with 81% growth year-over-year and reached profitability in 2025. For 2026, Alnylam's TTR franchise guidance of $4.4-4.7 billion represents 83% growth. However, the company expects a mid-single-digit net price decrease for Amvuttra in the U.S. in 2026, reflecting competitive pressures.
Key Strategic Insights for Alnylam Pharmaceuticals, Inc.
- Achieved profitability in 2025 after 15+ years of losses, marking transition to mature commercial-stage company
- Amvuttra captured 83% of product revenue in Q4 2025 with strong payer coverage (90%+ first-line) positioning for sustained growth
- Expanding into massive markets (hypertension with Roche, Alzheimer's) with proprietary RNAi platform beyond rare diseases
- Launching new siRELIS enzymatic-ligation manufacturing platform to reduce costs and expand capacity ($250M investment)
Recent Developments
- (Feb 2026) Reported $3B revenue (81% YoY growth) and achieved profitability for full year 2025
- (Jan 2026) Announced Alnylam 2030 strategy targeting ATTR leadership, innovation growth, and financial discipline
- (Feb 2026) Announced $250M manufacturing facility expansion to build proprietary siRNA production platform
Competitors & Competitive Landscape
- Pfizer — Oral TTR stabilizer, current market leader in ATTR with 2028 patent expiration
- BridgeBio — TTR stabilizer approved late 2024, closest competitor for first-line ATTR therapy
- Ionis/AstraZeneca — RNAi silencer with major advantage from AstraZeneca's cardiovascular sales force
The "War of the TTRs" is the primary 2026 competitive narrative. Alnylam faces Pfizer (Vyndaqel as current market share leader), BridgeBio (Attruby as closest competitor), and Ionis/AstraZeneca (Wainua silencer with massive cardiovascular sales force). Alnylam's first-mover advantage and superior outcomes data position it as the company to beat.
More Company Research
Ares Commercial Real Estate Corporation Capital A Berhad Bank Alfalah Limited STAAR Surgical Company NexPoint Residential Trust, Inc. Basic-Fit N.V. WeRide Inc. Jabal Omar Development Company ESR Group Limited ABB India Limited Royalty Pharma plc Aon plc Expion360 Inc. Enapter AG Siebert Financial Corp.Full Company Research Reports
Looking for a more in-depth analysis of Alnylam Pharmaceuticals, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.